Previous 10 | Next 10 |
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale, in a registered di...
Biora Therapeutics ( NASDAQ: BIOR ) is trading 9.5% higher after it completing an asset sale agreement to assign certain patent rights related to methods for determining the origin of cell-free DNA to Roche Diagnostics. The patent rights being assigned are directed to ...
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed a one-time asset sale agreement to assign certain patent rights related to methods for determining the or...
SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today presented detailed results from its PM-602 study titled “A scintigraphic study to evaluate the localization and delivery func...
SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the five posters presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, which is ...
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared a poster presented at the Parenteral Drug Association (PDA) Universe of Pre-Filled Syringes and Injection Devices Conference. The...
SAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today that the company will participate in the 12th annual Partnership Opportunities in Drug Delivery (PODD) Conference , October 24...
Biora Therapeutics ( NASDAQ: BIOR ) said on Tuesday the United States Patent and Trademark Office had issued a patent related to the company’s technologies for oral, systemic delivery of biologics, which uses an ingestible device designed to achieve systemic uptake thro...
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today that the United States Patent and Trademark Office (USPTO) has issued a patent related to the company’s technologies for o...
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical Advisory Board for Inflammatory Bowel Disease (IBD), which also...
News, Short Squeeze, Breakout and More Instantly...
Biora Therapeutics Inc. Company Name:
BIOR Stock Symbol:
NASDAQ Market:
Biora Therapeutics Inc. Website:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...